loading
전일 마감가:
$13.34
열려 있는:
$13.31
하루 거래량:
607.88K
Relative Volume:
0.59
시가총액:
$1.38B
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-5.9652
EPS:
-2.3
순현금흐름:
$-197.47M
1주 성능:
+3.08%
1개월 성능:
-5.12%
6개월 성능:
-6.16%
1년 성능:
+15.59%
1일 변동 폭
Value
$13.28
$13.91
1주일 범위
Value
$12.86
$13.91
52주 변동 폭
Value
$11.30
$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name
명칭
Day One Biopharmaceuticals Inc
Name
전화
650 484-0899
Name
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Name
직원
174
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
DAWN's Discussions on Twitter

DAWN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
DAWN 13.72 1.38B 0 -167.48M -197.47M -2.30
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-09 재확인 Needham Buy
2024-08-01 업그레이드 BofA Securities Underperform → Buy
2024-04-24 재확인 Needham Buy
2023-04-25 다운그레이드 BofA Securities Buy → Underperform
2023-02-08 개시 CapitalOne Overweight
2023-02-03 개시 Oppenheimer Perform
2022-12-15 개시 H.C. Wainwright Buy
2022-12-14 개시 Needham Buy
2022-12-05 개시 Goldman Buy
2022-12-01 개시 BofA Securities Buy
모두보기

Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스

pulisher
Nov 22, 2024

What Analysts Were Expecting After Day One Biopharmaceuticals Inc (NASDAQ: DAWN) fell -2.06% - Stocks Register

Nov 22, 2024
pulisher
Nov 22, 2024

When the Price of (DAWN) Talks, People Listen - Stock Traders Daily

Nov 22, 2024
pulisher
Nov 21, 2024

Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com Australia

Nov 21, 2024
pulisher
Nov 20, 2024

Day One Biopharmaceuticals announces R&D leadership change - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Day One Biopharmaceuticals announces executive retirement By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Day One Biopharmaceuticals, Inc. Announces the Retirement of Samuel Blackman as Co-Founder and Head of Research & Development, Effective at the End of 2024 - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Day one Biopharmaceuticals COO sells shares worth $34,372 By Investing.com - Investing.com South Africa

Nov 19, 2024
pulisher
Nov 19, 2024

Day One Biopharmaceuticals CEO sells $139,420 in stock - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Day one Biopharmaceuticals COO sells shares worth $34,372 - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Day One Biopharmaceuticals CEO sells $139,420 in stock By Investing.com - Investing.com UK

Nov 19, 2024
pulisher
Nov 19, 2024

First Turn Management LLC Invests $13.20 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Increase in Short Interest - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

First Week of July 2025 Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq

Nov 18, 2024
pulisher
Nov 18, 2024

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Day One Biopharmaceuticals to Present at Piper Sandler Healthcare Conference | DAWN Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024
pulisher
Nov 11, 2024

(DAWN) Trading Advice - Stock Traders Daily

Nov 11, 2024
pulisher
Nov 11, 2024

TimesSquare Capital Management LLC Has $25.46 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in Stock - MarketBeat

Nov 09, 2024
pulisher
Nov 07, 2024

FMR LLC Bolsters Position in Day One Biopharmaceuticals Inc - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 06, 2024
pulisher
Nov 05, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded at TD Cowen - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock By Investing.com - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Day one biopharmaceuticals head of R&D sells $8,010 in stock - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Forecast: Analysts Think Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Business Prospects Have Improved Drastically - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Equities Analysts Issue Forecasts for DAWN Q1 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

(DAWN) Proactive Strategies - Stock Traders Daily

Oct 31, 2024
pulisher
Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results, Beats Estimates By $0.58 EPS - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Pre-Market Trading Boosts Day One (DAWN) Amid High OJEMDA Demand - Stocks Telegraph

Oct 31, 2024
pulisher
Oct 31, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

ChromaDex Q3 2024 Earnings Preview - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Day One Biopharmaceuticals Reports Strong Q3 Growth - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Day One Biopharmaceuticals earnings beat by $0.99, revenue topped estimates - Investing.com UK

Oct 30, 2024
pulisher
Oct 30, 2024

DAWNDay One Biopharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Oct 30, 2024
pulisher
Oct 30, 2024

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress - The Manila Times

Oct 30, 2024
pulisher
Oct 30, 2024

Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 30, 2024
pulisher
Oct 23, 2024

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpStill a Buy? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

Day One Biopharma shares retain overweight rating on ojemda drug usage - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

Global Cancer Antibody Drug Conjugates Market Size Forecast 2030 - GlobeNewswire Inc.

Oct 22, 2024
pulisher
Oct 21, 2024

Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet - Yahoo Finance

Oct 21, 2024
pulisher
Oct 21, 2024

DAWN Q3 EPS Estimate Boosted by Capital One Financial - MarketBeat

Oct 21, 2024

Day One Biopharmaceuticals Inc (DAWN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Day One Biopharmaceuticals Inc 주식 (DAWN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Blackman Samuel C.
HEAD OF R&D
Nov 18 '24
Sale
13.21
2,206
29,142
1,064,015
Dubow Adam
GENERAL COUNSEL
Nov 18 '24
Sale
13.21
3,165
41,810
32,162
York Charles N II
COO, CFO AND SECRETARY
Nov 18 '24
Sale
13.21
2,602
34,373
240,133
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):